April 19, 2017 / 8:46 PM / 4 months ago

BRIEF-TESARO announces availability of ovarian cancer drug in U.S.

April 19 (Reuters) - TESARO Inc-

* TESARO announces availability of zejula™ (niraparib) for patients with recurrent ovarian cancer in the U.S.

* Tesaro inc says wholesale acquisition cost of zejula is $9,833 for a one-month supply of zejula at a dose of 200 milligrams once per day Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below